Document:

ex10w1

 

Exhibit 10.1

EMPLOYMENT AGREEMENT

     This Employment Agreement (this “Agreement”), is made and entered into this 14th
day of February, 2006 (the “Effective Date”), by and between Cyberkinetics Neurotechnology Systems,
Inc., a Delaware corporation (the “Company”), and Mark A. Carney (the “Executive”).

          Whereas, the parties wish to set forth their understanding and agreement regarding the
employment of the Executive by the Company;

          Now therefore, in consideration of the mutual covenants herein contained, the parties hereto
agree as follows:

Section 1. Employment Services.

     During the Employment Period (as defined below), the Executive will serve as the Company’s
Executive Vice President and will have such duties and responsibilities as would normally attach to
those positions, including such duties and responsibilities as are customary among persons employed
in similar capacities for similar companies, subject to the authority of the CEO and President of
the Company. The Executive will faithfully and diligently carry out his duties and
responsibilities and comply with all of the reasonable and lawful directives of the CEO, to which
the Executive will report. The Executive will, if so elected, serve as a director of the Company
and, if requested by the Company, an officer or director of any subsidiary or affiliate of the
Company without compensation in addition to that provided in this Agreement. For purposes of this
Agreement, an “affiliate” of the Company means any corporation, limited partnership, limited
liability company or other entity engaged in the same business as the Company, or a related
business, and which is controlled by or is under common control with the Company.

Section 2. Term.

     The Company shall employ the Executive, and the Executive accepts such employment, commencing
on the Effective Date and continuing thereafter until such time as this Agreement has terminated
under the provisions of Section 5 hereof (the “Employment Period”).

Section 3. Performance.

     During the Employment Period, the Executive shall devote his best efforts and all of his
business time and attention (except for vacation periods and reasonable periods of illness or other
incapacity) to the business of the Company and its affiliates and will not engage in consulting
work or in any other trade or business for his own account or for or on behalf of any other person,
firm or corporation without the written consent of the Board of Directors of the Company (the
“Board”) in each case, which shall not be granted if any such activity, in the opinion of the
Board, competes, conflicts or interferes with the performance of his duties hereunder in any
material way; provided, however, the Company acknowledges and agrees that the Executive may devote
no more than

 

 

one and one-half days per calendar quarter in the aggregate to the entities listed on Exhibit
A attached hereto and incorporated herein which activity shall not be a breach of this Section
3.

Section 4. Compensation and Benefits.

	 	(a)	 	Salary. For services to the Company rendered by the Executive in any
capacity during the Employment Period, including, without limitation, services as a
manager, officer, director or member of any committee of the Company or of any
subsidiary, affiliate or division thereof, the Company will pay or cause to be paid
to the Executive a base salary at the rate of not less than $212,000 per annum (or
such higher amount as the Compensation Committee of the Board (the “Compensation
Committee”), if any, may establish from time to time). The Executive’s base salary
for any partial year will be prorated based upon the number of days elapsed in such
year. The Executive’s base salary will be payable periodically in accordance with
the Company’s customary payroll practices for its executives. Such base salary
shall be reviewed at least annually after the end of each fiscal year, starting
with the fiscal year ending December 31, 2006, and may be increased based on the
Executive’s performance, but not decreased, by the Board (or the Compensation
Committee) in its reasonable discretion, to be effective in the first pay period of
the ensuing January, starting with January 2007. The term “base salary” shall not
include any payment or other benefit which is denominated as or is in the nature of
a bonus, incentive payment, profit-sharing payment, performance share award, stock
option, stock appreciation right, retirement or pension accrual, insurance benefit,
other fringe benefit or expense allowance, whether or not taxable to the Executive
as income.
	 
	 	(b)	 	Annual Performance Bonus. The Executive will be eligible to receive an
annual cash performance bonus of up to $100,000 (the “Annual Performance Bonus”).
The Compensation Committee shall consider and make a bonus determination not later
than 90 days after the end of each fiscal year during the Employment Period,
starting with the fiscal year ending December 31, 2006. Bonus awards shall be
based upon the performance by the Executive as measured against objective and
reasonable criteria mutually agreed and approved in advance by the Executive and
the Compensation Committee, which criteria shall be set forth in Schedule 1 to this
Agreement. To the extent that at least 50% of the criteria are achieved, the
Executive shall be paid a pro rata percentage of the Annual Performance Bonus. In
the event Executive exceeds such criteria set forth in Schedule 1 to this
Agreement, the Compensation Committee may in its sole and absolute discretion
increase the Annual Performance Bonus to an amount greater than $100,000.

-2-

 

	 	(c)	 	Candidacy for COO Position. Until the third anniversary of the
Effective Date of this Agreement, the Company agrees that the Executive will be
considered as a candidate for the position of Chief Operating Officer of the
Company, should such position be created. If the Executive is offered such a
position and the Executive declines the offer due to the requirements of the
geographic location of the position, such event will not be considered a “Deemed
Termination Event” (as defined below) unless he is thereafter terminated by the
Company solely for declining such offer.
	 
	 	(d)	 	Stock Option Grant. Simultaneously with the execution and delivery of
this Agreement, the Company hereby grants to the Executive an incentive stock
option to purchase up to 100,000 shares of the Company’s Common Stock (the
“Option”) pursuant to the terms and conditions of that certain Option Agreement, a
copy of which is attached hereto and incorporated herein as Exhibit B (the
“Option Agreement”). Under the terms of the Option Agreement, the Option will have
an exercise price equal to the fair value of the Company’s Common Stock as of the
Effective Date and the shares of the Company’s Common Stock granted under the
Option will become vested and exercisable over a period of four years as follows:
(i) 25% on the first anniversary of the Effective Date and (ii) an additional 6.25%
shall vest every three months after the first anniversary of the Effective Date for
the next three years, as long as the Executive continues to be engaged by the
Company on each successive vesting date under the terms and conditions of this
Agreement (or another agreement mutually agreed upon). The Option will have a term
of ten (10) years from the Effective Date.
	 
	 	(e)	 	Accelerated Vesting of Stock Options. Upon any sale, merger or other
transaction resulting in a change in control of the Company in which the per share
consideration to be received by the stockholders of the Company is equivalent to at
least $6 per share, any unvested options to purchase shares of the Company’s Common
Stock granted to Executive pursuant to Section 4(d) above which remain outstanding
immediately prior to the effective date of the change in control shall vest and
become exercisable immediately prior to such sale, merger or other change of
control transaction. For purposes of this Section 4(e), a change of control shall
be deemed to occur upon: (1) any sale or exchange of greater than 50% of the
voting interest of the Company; (2) any merger of the Company with an unaffiliated
third party in which the Company does not survive the merger; or (3) any sale of
all or substantially all assets of the Company.
	 
	 	(f)	 	Other Benefits. In addition to the compensation described in this
Section 4, and such other amounts not constituting base salary as may be provided
to the Executive from time to time by the Board, the Executive will be entitled
during the Employment Period to participate in any retirement plans, bonus plans,
welfare benefit plans and other employee

-3-

 

	 	 	 	benefit plans of the Company that may be in effect from time to time with respect to
executives of the Company generally, to the extent the Executive is eligible under
the terms of those plans. Executive shall also be entitled to the following:

	 	•	 	Twenty days of paid vacation per year.
	 
	 	•	 	The Company shall also reimburse the Executive in accordance with the
Company’s reimbursement policy for all reasonable and necessary business
expenses incurred by him in the course of performing his duties hereunder,
provided that such expenses are appropriately documented in accordance with
the Company’s reimbursement policy.
	 
	 	•	 	Executive shall be entitled to a life insurance policy in a face amount
equal to Three Hundred Thousand Dollars ($300,000) (the Life Insurance”),
which such policy shall be convertible to an individual policy at the
election of Executive upon termination of Executive’s employment with the
Company.

Section 5. Termination.

     The Executive’s employment hereunder shall terminate under the following circumstances:

	 	(a)	 	Death or Disability. The Executive’s employment with the Company shall
automatically terminate upon the death or Disability (as hereinafter defined) of
the Executive. “Disability” shall mean that the Executive is no longer able to
perform the essential functions of the Executive Vice President for a continuous
period of six (6) months or a total of nine (9) months in any one-year period. If
any question arises as to whether the Executive has been so disabled, the Executive
shall submit to an examination by a physician mutually acceptable to the Board and
the Executive and following such examination, the physician shall submit to the
Company and to the Executive a report in reasonable detail setting forth his or her
opinion as to whether the Executive was so disabled. Such report shall for the
purposes of this Agreement be conclusive of the issue. Notwithstanding the
foregoing, in the event of a Disability, the Company shall take no action that
violates the applicable provisions of the Americans With Disabilities Act. If the
Executive’s employment with the Company is terminated due to the death or
Disability of the Executive, then Company shall promptly pay (and in any event no
later than five (5) days after the date of death or Disability) to the Executive’s
estate or to the Executive any and all amounts then owed to the Executive,
including all accrued and unpaid base salary, vacation pay, other benefits, and any
applicable earned portion of the Annual Performance Bonus less any applicable
withholdings. In addition, the Executive shall also be entitled to

-4-

 

	 	 	 	reimbursement of any reimbursable business expenses which were incurred by Executive
through and including the date of death or Disability, which shall be paid in
accordance with the Company’s expense reimbursement policy. With respect to a
termination due to Disability, the Executive shall be entitled to convert the Life
Insurance into an individual policy.
	 
	 	(b)	 	Termination by the Company without Cause. The Company may, at any time
by action of a majority of the entire membership of its Board not including
Executive, terminate the Executive’s employment without Cause (as defined below) by
giving the Executive written notice of the effective date of termination (which
effective date may be the date of such written notice) (the “Date of Termination”).
If the Executive voluntarily resigns his employment with the Company during the
three-year period following the Effective Date of this Agreement due to a material
reduction in the Executive’s responsibilities or title, or due to a material
reduction in the Executive’s base salary without a corresponding pro rata reduction
in the base salary of the Company’s other executives, or due to the Company
requiring the Executive to relocate more than 50 miles from Indianapolis, Indiana,
or due to a breach of this Agreement by the Company (each a “Deemed Termination
Event”), such voluntary resignation will be deemed to be termination by the Company
without Cause. The Executive will provide thirty (30) days prior written notice to
the Company of any such voluntary resignation by reason of a Deemed Termination
Event, and during such 30-day period the Company shall have an opportunity to cure
the Deemed Termination Event (the actual date of termination of the Executive’s
employment as a result of a resignation due to a Deemed Termination Event is also
referred to herein as the “Date of Termination”). If a cure is effected within
such 30-day period, the provisions of this Section 5(b) shall no longer be
applicable with respect to the Deemed Termination Event so cured. If the Executive
resigns his employment due to a Deemed Termination Event or the Executive is
terminated without Cause by the Company, any unvested options granted hereunder
that, absent such termination, that would have otherwise vested in the 12 month
period following the date of termination shall immediately vest and be exercisable.
If the Company shall terminate the Executive without Cause hereunder or the
Executive resigns his employment due to the occurrence of a Deemed Termination
Event, the Company shall have the obligation to pay the Executive the following:

	 	(1)	 	Any and all amounts owed to the Executive through the Date of
Termination, including all accrued salary, vacation pay, and any other
benefits, which shall be payable in a lump sum payment less any applicable
withholdings within five (5) business days (for purposes of this Agreement, a
“business day” shall mean any day other than Saturday, Sunday or any day on
which banks in the

-5-

 

	 	 	 	Commonwealth of Massachusetts are authorized by law to close) following the
Date of Termination.
	 
	 	(2)	 	Each month for a period of twelve (12) months following the
Date of Termination (the “Severance Period”), the Company shall pay the
Executive, as a severance payment, 100% of the Executive’s Monthly Salary (as
defined below), less required withholdings. Such amounts shall be payable
periodically in accordance with the Company’s customary payroll practices.
Within six months following the end of the Severance Period, the Executive
shall reimburse the Company for any severance amounts paid to the Executive to
the extent the Executive has earned or received income from other sources
(excluding directors’ fees and investment income) during the Severance Period
and reportable as earnings on Form W-2 or Form 1099 (the “Supplementary
Income”). Notwithstanding the foregoing, the Executive shall not be obligated
to reimburse the Company for any amounts in excess of the aggregate amount paid
by the Company to the Executive during the Severance Period and the Executive
shall have no affirmative duty to seek alternative employment or otherwise
mitigate the costs and expenses the Company is required to pay or incur during
the Severance Period. For purposes hereof, “Monthly Salary” shall mean the
Executive’s annual base salary in effect immediately prior to the Date of
Termination (except if the termination is due to a reduction in salary, then
the annual base salary in effect immediately prior to the decrease in annual
base salary) divided by twelve (12).
	 
	 	(3)	 	A bonus, equal to the average of the Annual Performance Bonuses
earned by the Executive in each of the two (2) years prior to his termination
of employment (or if the Executive has not been employed for two full years, an
assumed bonus of $50,000 for each year which the Executive was not employed
during the full year), which shall be payable in a lump sum payment within five
(5) business days after the Date of Termination.
	 
	 	(4)	 	The Executive may continue to participate in the Company’s
group health, life and dental plans during the Severance Period at the same
cost to him as in effect prior to his termination of employment.
	 
	 	(5)	 	Notwithstanding anything to the contrary herein, in the event
that the Executive materially breaches Sections 6, 7, 8 or 9 of this Agreement,
which breach, if reasonably capable of being cured, is not cured within thirty
(30) days after receipt of written notice from the Company, the Company’s
obligations under subsections (2) through (5) above shall cease in their
entirety.

-6-

 

	 	(6)	 	The Executive shall be entitled to reimbursement of any
reimbursable business expenses which were incurred prior to the Termination
Date which shall be paid by the Company in accordance with the Company’s
expense reimbursement policy.
	 
	 	(7)	 	The Executive shall be entitled to convert the Life Insurance
into an individual policy if the policy provides for such conversion.

	 	(c)	 	Termination by the Company for Cause. The Company shall have the right
to terminate the Executive’s employment effective immediately for any of the
following reasons (each of which is referred to herein as “Cause”) by giving the
Executive written notice which specifically identifies the Cause in reasonable
detail:

	 	(1)	 	the breach of any provision of this Agreement, which breach, if
reasonably capable of being cured, is not cured within thirty (30) days after
receipt of written notice from the Company;
	 
	 	(2)	 	any act of willful disloyalty, dishonesty, or breach of
fiduciary duty with respect to any aspect of the Company’s or any affiliate’s
business;
	 
	 	(3)	 	any act of fraud or embezzlement;
	 
	 	(4)	 	deliberate disregard of a rule or policy of the Company known
by the Executive or contained in a policy and procedure manual provided to the
Executive which results in material loss, damage or injury to the Company and
is not cured with thirty (30) days after receipt of written notice from the
Company; or
	 
	 	(5)	 	conviction of a felony.

If the Executive’s employment is terminated by the Company pursuant to this Section 5(c),
then (i) the Company shall have no further obligations hereunder accruing from and after the
effective date of termination and shall have all other rights and remedies available under
this or any other agreement and at law or in equity; and (ii) any unvested options granted
hereunder shall immediately expire. Notwithstanding the foregoing, the Company shall
promptly pay (and in any event within five (5) business days after the date of termination)
to the Executive on the effective termination date any and all amounts then owed to the
Executive, including all accrued salary, vacation pay, other benefits and any applicable
earned portion of the Annual Performance Bonus less any applicable withholdings. In
addition, the Executive shall also be entitled to reimbursement of any reimbursable business
expenses which were incurred by Executive through and including the date of termination,
which shall be paid by the Company in accordance with the Company’s expense reimbursement
policy. The Executive shall be entitled to convert the Life Insurance into an individual
policy.

-7-

 

	 	(d)	 	Resignation by the Executive. The Executive may resign his employment
with the Company under this Agreement at any time upon thirty (30) days prior
written notice to the Company. The Board may, in such event, elect to waive the
period of notice, or any portion thereof, in which event the Executive’s date of
resignation shall be that date within such thirty (30) day notice period determined
by the Board. Upon resignation by the Executive of his employment with the Company
for any reason other than the occurrence of a Deemed Termination Event under
Subsection 5(b) hereof (in which case the provisions of Section 5(b) hereof shall
be applicable): (i) the Company shall have no further obligations hereunder
accruing from and after the effective date of termination; and (ii) any unvested
options granted to the Executive shall immediately expire. Notwithstanding the
foregoing, the Company shall pay to the Executive within five (5) business days
after the effective termination date any and all amounts then owed to the
Executive, including all accrued salary, vacation pay, other benefits and any
earned portion of the Annual Performance Bonus less any applicable withholdings. In
addition, the Executive shall also be entitled to reimbursement of any reimbursable
business expenses which were incurred by Executive through and including the
effective date of the termination, which shall be paid by the Company in accordance
with the Company’s expense reimbursement policy after the submission of a written
expense report by the Executive. The Executive shall be entitled to convert the
Life Insurance into an individual policy.

Section 6. Confidential Information

	 	(a)	 	While employed by the Company and thereafter, the Executive shall not,
directly or indirectly, disclose to anyone outside of the Company any Confidential
Information (as hereinafter defined) or use any Confidential Information other than
pursuant to Executive’s employment by, and for the benefit of, the Company.
	 
	 	(b)	 	The term “Confidential Information,” as used throughout this Agreement,
means all data or information not generally known outside of the Company whether
prepared or developed by or for the Company or received by the Company from an
outside source. Without limiting the scope of this definition, Confidential
Information includes any trade secrets, any technical data, design, pattern,
formula, computer program, source code, object code, algorithm, manual, product
specification, systems, methods, processes or plan for a new or revised product;
and any business, marketing, financial, or sales record, data, plan, or survey; and
any other record or information relating to the present or future business or
products of the Company. All Confidential Information and copies thereof are the
sole property of the Company.

-8-

 

Section 7. Noncompetition and Nonsolicitation

     (a) During the term of the Executive’s employment by the Company under this Agreement
and for a period equal to the greater of (i) twelve (12) months following termination of the
Executive’s employment, however caused, and (ii) the noncompetition period set forth in an
Investment Representation Letter submitted to the Company by the Executive on or about the
date hereof, the Executive shall not, without the prior written consent of the Company:

	 	(1)	 	For himself or on behalf of any other person or entity,
directly or indirectly, either as principal, agent, stockholder, employee,
consultant, representative or in any other capacity, own, manage, operate or
control, or be connected or employed by, or otherwise associate in any manner
with, engage in or have a financial interest in any business which is directly
or indirectly competitive with the Company’s Business (as defined below), or
any of its affiliates, except that nothing contained herein shall preclude the
Executive from purchasing or owning stock in any such business if such stock is
publicly traded and provided that the Executive’s holdings do not exceed three
percent (3%) of the issued and outstanding capital stock of such business.
Notwithstanding anything in this Agreement to the contrary, the Executive shall
not be precluded from employment by a business with multiple business units or
divisions, so as the business unit or division in which he is employed is not
competitive with the Company’s Business.
	 
	 	(2)	 	Either individually or on behalf of or through any third party,
solicit, divert or appropriate or attempt to solicit, divert or appropriate,
for the purpose of competing with the Company or any present or future parent,
subsidiary or other affiliate of the Company which is engaged in a similar
business as the Company’s Business, any customers or patrons of the Company, or
any prospective customers or patrons with respect to which the Company has
developed or made a sales presentation (or similar offering of services).
	 
	 	(3)	 	Either individually or on behalf of or through any third party,
directly or indirectly, solicit, entice or persuade or attempt to solicit,
entice or persuade any other employees of or consultants to the Company within
the immediately preceding 12-month period or any parent or affiliate of the
Company to leave the services of the Company or any parent or affiliate for any
reason.
	 
	 	(4)	 	For purposes of this Section 7, the Company’s business
(“Business”) shall mean researching, developing or commercializing therapeutic
and diagnostic devices and drugs for the diagnosis and treatment of central
nervous system injury and disease; provided that the term “Business” shall be
deemed

-9-

 

	 	 	 	amended to reflect any change in the Company’s Business after the Effective
Date but prior to the Executive’s termination or resignation of employment
with the Company. A business will be deemed to be competitive with the
Company if it is engaged in a business substantially similar, in whole or in
part, to the Company’s Business.

Section 8. Ownership of Ideas, Copyrights and Patents.

     (a) The Executive agrees that all ideas, discoveries, creations, manuscripts and
properties, innovations, improvements, know-how, inventions, designs, developments,
apparatus, techniques, methods, processes and formulae (all of the foregoing being
hereinafter referred to as “the inventions”) which may be used in the business of the
Company, or any of its affiliates, whether patentable, copyrightable or not, which the
Executive may conceive or develop during his employment with the Company, or any of its
affiliates, alone or in conjunction with another or others, whether during or out of regular
business hours, and whether at the request or upon the suggestion of the Company, or any of
its affiliates, or otherwise, shall be the sole and exclusive property of the Company, or
any of its affiliates, and that the Executive shall not publish any of the inventions
without the prior written consent of the Company. The Executive hereby assigns to the
Company all of his right, title and interest in and to all of the foregoing.
Notwithstanding the foregoing, the provisions of this Section 8 do not apply to inventions
for which no equipment, supplies, facility, resources or Confidential Information of the
Company was used and was developed entirely on the Executive’s own time, unless the
invention relates to the Company’s business, to the Company’s actual or demonstrably
anticipated research or development, or the invention results from any work performed by the
Executive for the Company or any if its affiliates. Executive agrees to provide the Company
promptly with notice and sufficient documentation of any such inventions so that the Company
may evaluate the inventions and determine whether such inventions should be assigned to the
Company.

     (b) The Executive agrees that, at the Company’s expense, he will fully cooperate with
the Company, its attorneys and agents, at any time during or after his employment, in the
preparation and filing of all papers and other documents as may be required to perfect the
Company’s rights in and to any of such inventions, including, but not limited to, joining in
any proceeding to obtain letters patent, copyrights, trademarks or other legal rights in the
United States and in any and all other countries on such inventions, provided that the
Company will bear the expense of such proceedings, and that any patent or other legal rights
so issued to the Executive personally, shall be assigned by the Executive to the Company.

Section 9. Disclosure of Covenants and Return of Records.

     (a) The Executive agrees that he will provide, and that the Company may in its
discretion similarly provide, a copy of the covenants contained in

-10-

 

Sections 6, 7, and 8 of this Agreement to any business or enterprise which the
Executive may directly or indirectly own, manage, operate, finance, join, control or
participate in the ownership, management, operation, financing, control or control of, or
with which the Executive may be connected as an officer, director, employee, partner,
principal agent, representative, consultant or otherwise.

     (b) Upon termination of the Executive’s employment with the Company, the Executive
shall deliver to the Company any property of the Company which may be in the Executive’s
possession, including, without limitation, products, materials, memoranda, notes, records,
reports, or other documents or photocopies of the same.

Section 10. Conflicting Agreements.

     The Executive hereby warrants and covenants that his employment by the Company will not result
in a breach of the terms, conditions or provisions of any agreement to which the Executive is
subject, and that he has not made and will not make any agreements in conflict with this Agreement.

Section 11. Successors and Assigns.

     This Agreement is intended to bind and inure to the benefit of and be enforceable by the
Executive and the Company, except that the Executive may not assign any of his rights or
obligations under this Agreement and the Company may not assign any of its rights or obligations
under this Agreement without the prior written consent of the other party.

Section 12. Severability.

     Whenever possible, each provision of this Agreement will be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be
invalid, illegal or unenforceable in any respect under applicable law or rule in any jurisdiction,
such invalidity, illegality or unenforceability will not affect such provision in any other
jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as
if such invalid, illegal or unenforceable provision had never been contained herein.

Section 13. Notice.

     Any notice provided for in this Agreement must be in writing and must be either personally
delivered, mailed by first class mail (postage prepaid and return receipt requested), sent by
facsimile transmission or sent by reputable overnight courier service, to the recipient at the
address indicated below:

	 	 	 	 	 
	 

	 	To the Company:
	 	Cyberkinetics Neurotechnology Systems, Inc.
	 

	 	 	 	100 Foxborough Boulevard, Suite 240
	 

	 	 	 	Foxborough, MA 02035
	 

	 	 	 	Facsimile: 508-549-9985

-11-

 

	 	 	 	 	 
	 

	 	To the Executive:
	 	Mark A. Carney
	 

	 	 	 	 
	 

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	With a copy to:
	 	Ice Miller LLP
	 

	 	 	 	One American Square
	 

	 	 	 	Suite 3100
	 

	 	 	 	Indianapolis, Indiana 46282
	 

	 	 	 	Attn: John R. Thornburgh
	 

	 	 	 	Facsimile: (317) 592-4783

or to such other address or to the attention of such other person as the recipient party shall have
specified by prior written notice to the sending party. Any notice under this Agreement will be
deemed to have been given when so delivered or sent or if mailed, five days after so mailed.

Section 14. Amendments and Waivers.

     Any provision of this Agreement may be amended or waived only with the prior written consent
of the Executive and a majority of the Compensation Committee. Notwithstanding the foregoing, the
failure of either party to require the performance of any term or obligation of this Agreement, or
the waiver by either party of any breach of this Agreement, shall not prevent any subsequent
enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

Section 15. Entire Agreement.

     This Agreement (and the Option Agreement referenced herein) embodies the complete agreement
and understanding between the parties and supersedes and preempts any prior understandings,
agreements or representations by or between the parties, written or oral, other than the applicable
provisions of the Investment Representation Letter provided to the Company by the Executive, which
may have related to the subject matter hereof in any way.

Section 16. Governing Law.

     All questions concerning the construction, validity and interpretation of this agreement will
be governed by the internal law, and not the law of conflicts, of the Commonwealth of
Massachusetts.

Section 17. Remedies.

     Each of the parties to this Agreement will be entitled to enforce his or its rights under this
Agreement specifically, to recover damages (including, without limitation, reasonable fees and
expenses of counsel) by reason of any breach of any provision of this Agreement and to exercise all
other rights existing in his or its favor. The parties hereto agree and acknowledge that money
damages may not be an adequate remedy for any breach or threatened breach of the provisions of this
Agreement and that any

-12-

 

party may in his or its sole discretion apply to any court of law or equity of competent
jurisdiction for specific performance and/or injunctive relief in order to enforce or prevent any
violations of the provisions of this Agreement.

Section 18. Captions.

     The captions set forth in this Agreement are for convenience only, and shall not be considered
as part of this Agreement or as in any way limiting or amplifying the terms and provisions hereof.

Section 19. Representations and Warranties of Executive.

     The Executive represents and warrants to the Company that to the best of his actual knowledge,
after reasonable inquiry, all of the representations and warranties of Andara Life Science, Inc.
under that certain Agreement and Plan of Merger, dated of even date herewith, by and among the
Company, Andara Acquisition Corp. and Andara Life Science, Inc. are true, correct and complete in
all material respects as of the date such representations and warranties were made.

[This space intentionally left blank.]

-13-

 

     In witness whereof, the parties have signed, sealed and delivered this Agreement as of the
Effective Date.

	 	 	 	 	 
	 	CYBERKINETICS NEUROTECHNOLOGY SYSTEMS, INC.

 	 
	 	By:  	/s/ Timothy R. Surgenor
 	 
	 	 	Timothy R. Surgenor 	 
	 	 	President and Chief Executive Officer 	 
	 

	 	 	 	 	 
	 	EXECUTIVE:

 	 
	 	 	/s/ Mark A. Carney
 	 
	 	 	Mark A. Carney 	 
	 	 	 
	 

 

 

SCHEDULE 1

TO

EMPLOYMENT AGREEMENT

ANNUAL PERFORMANCE BONUS CRITERIA

The Company and the Executive agree that the provisions of this Schedule 1 shall be determined by
the mutual agreement of the parties no later than March 31, 2006.

 

 

EXHIBIT A

Entities

MFS Bioscience, Inc. (Board and Founder)

InterMARK Technologies, Inc. (Owner)

Sb2 (Board and Founder)

Specialty Risk International, Inc. (Shareholder)

 

 

EXHIBIT B

Option AgreementEXHIBIT 10.12

                                 AMENDMENT NO. 2
                                       TO
                                MERGER AGREEMENT

         AMENDMENT NO. 2, dated as of February 15, 2006, to the Agreement and
Plan of Merger ("Merger Agreement"), dated as of October 20, 2005, by and among
Tremisis Energy Acquisition Corporation, RAM Energy Acquisition, Inc., RAM
Energy, Inc. ("RAM"), and each of the Stockholders of RAM, as amended by
Amendment No. 1 thereto dated November 11, 2005.

         IT IS HEREBY AGREED that the Merger Agreement, as heretofore amended,
is further amended as follows:

              1.   Section 1.6(a), as heretofore amended, is hereby amended to
read as follows:

         "(a) Conversion of Company Common Stock. Other than any shares to be
         canceled pursuant to Section 1.6(c), each share of common stock, par
         value $10.00, of the Company ("Company Common Stock") issued and
         outstanding immediately prior to the Effective Time will be
         automatically converted (subject to Section 1.6(f)) into the right to
         receive on the Closing Date (i) that number of shares of common stock,
         par value $0.0001, of Parent ("Parent Common Stock") determined by
         dividing the Aggregate Parent Common Stock Number by the Outstanding
         Company Stock Number, and (ii) that amount of cash determined by
         dividing the Aggregate Cash Number by the Outstanding Company Stock
         Number. The term "Aggregate Parent Common Stock Number" shall mean
         25,600,000. The term "Outstanding Company Stock Number" shall mean the
         number of shares of Company Common Stock outstanding on the Closing
         Date, after giving effect to all stock option exercises contemplated
         hereby. The term "Aggregate Cash Number" shall mean the lesser of (I)
         $30,000,000, and (II) the amount of cash distributed to Parent from the
         Trust Fund at the Closing (after payment to those stockholders of
         Parent who elect to have their shares converted to cash in accordance
         with Parent's Charter Documents (as defined in Section 2.1(a)), less
         the sum of all expenses reasonably incurred by Parent in connection
         with the transaction contemplated hereby."

              2.   Section 3.15(c) is hereby amended to read as follows:

         "(c) Parent has not been delinquent in the payment of any material Tax
         that has not been accrued for in Parent's books and records of account
         for the period for which such Tax relates nor is there any material Tax
         deficiency outstanding, proposed or assessed against Parent, nor has
         Parent executed any unexpired waiver of any statute of limitations on
         or extending the period for the assessment or collection of any Tax."

              3.   The last sentence of paragraph (d) of Schedule 4.1 is hereby
 amended to read as follows:

         "Prior to the Closing, the Company will continue to pay ordinary
         quarterly dividends to

         the Stockholders consistent with historical practices and with the
         restrictions imposed under the Loan Agreement, including payment of a
         $500,000 dividend during the fourth quarter of 2005 and a $500,000
         dividend during the first quarter of 2006."

              4.   A new Section 5.19 is hereby added to the Merger Agreement,
to read as follows:

         "5.19 Stockholder Obligations. The Stockholders shall repay to the
         Company, on or before the Closing, all direct and indirect indebtedness
         and obligations owed by them to the Company, including the indebtedness
         and other obligations described in Schedule 2.22 and all other amounts
         owed by REPCO (as defined in Schedule 2.22) to the Company."

              5.   Section 6.3(i), as heretofore amended, is hereby amended to
read as follows:

         "(i) Company Indebtedness. The Adjusted Indebtedness for Borrowed Money
         of the Company, including the Subsidiaries, shall not exceed
         $125,000,000. As used herein, the term "Adjusted Indebtedness for
         Borrowed Money" shall mean the sum of all indebtedness of the Company
         for borrowed money, less (1) the amount of any cash deposits posted by
         the Company as security in connection with outstanding Company hedging
         contracts, (2) the positive difference, if any, between $30,000,000 and
         the Aggregate Cash Number, (3) an amount up to $6.0 million for
         aggregate fees, costs and expenses paid by the Company in connection
         with replacing, enhancing or improving its existing credit facilities
         in a manner that, on the whole, is quantitatively more beneficial to
         the Company and (4) capital expenditures incurred by the Company after
         March 1, 2006."

              6.   A new Section 6.3(k) is hereby added to the Merger Agreement,
to read as follows:

         "(k) Stockholder Obligations. The Stockholders shall have repaid to the
         Company, on or before the Closing, all direct and indirect indebtedness
         and obligations owed by them to the Company, including the indebtedness
         and other obligations described in Schedule 2.22 and all other amounts
         owed by REPCO (as defined in Schedule 2.22) to the Company."

              7.   The last sentence of Section 7.4(b) is hereby amended to read
as follows:

         "Notwithstanding the foregoing, payments made with respect to
         indemnifiable Losses arising out of the Great Plains Claim shall not be
         applied toward the Deductible and the Deductible shall not apply to
         indemnifiable Losses arising out of the Great Plains Claim."

              8.   Section 8.1(b) is hereby amended to read as follows:

         "(b) by either Parent or the Company if the Proxy Statement shall not
         have been mailed to the record owners of Parent Common Stock on or
         before April 27, 2006."

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2
to the Merger Agreement to be executed as of the date first written above.

                            TREMISIS ENERGY ACQUISITION CORPORATION

                            By: /s/ Lawrence S. Coben
                                ---------------------
                                Lawrence S. Coben
                                Chairman & CEO

                            RAM ENERGY ACQUISITION, INC.

                            By: /s/ Lawrence S. Coben
                                ---------------------
                                Lawrence S. Coben
                                Chairman & CEO

                            RAM ENERGY, INC.

                            By:  /s/ Larry E. Lee
                                 ----------------
                                 Larry E. Lee
                                 President & CEO

                            STOCKHOLDERS:

                         [SEE SEPARATE SIGNATURE PAGES.]

                  STOCKHOLDER SIGNATURE PAGE TO AMENDMENT NO. 2
                               TO MERGER AGREEMENT

/s/ Larry E. Lee
----------------
Larry E. Lee

DANISH KNIGHTS, A LIMITED PARTNERSHIP,
A Texas Limited Partnership

By: Dannebrog Corp., General Partner

By: /s/ Britani Talley Bowman
    -------------------------
     Britani Talley Bowman
     President

The undersigned agrees that, upon exercise of the stock option referred to in
Section 1.13 of the Merger Agreement, he shall be considered to be, and shall
be, a Stockholder (as defined therein) for all purposes of such Merger
Agreement, as amended hereby.

/s/ C. David Stinson
--------------------
C. David Stinson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]